[go: up one dir, main page]

IL178300A0 - Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease - Google Patents

Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Info

Publication number
IL178300A0
IL178300A0 IL178300A IL17830006A IL178300A0 IL 178300 A0 IL178300 A0 IL 178300A0 IL 178300 A IL178300 A IL 178300A IL 17830006 A IL17830006 A IL 17830006A IL 178300 A0 IL178300 A0 IL 178300A0
Authority
IL
Israel
Prior art keywords
depression
patients
prevention
treatment
fatty acids
Prior art date
Application number
IL178300A
Other languages
English (en)
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of IL178300A0 publication Critical patent/IL178300A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL178300A 2004-04-16 2006-09-26 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease IL178300A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101578 2004-04-16
PCT/EP2005/004031 WO2005110393A1 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Publications (1)

Publication Number Publication Date
IL178300A0 true IL178300A0 (en) 2007-02-11

Family

ID=34928968

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178300A IL178300A0 (en) 2004-04-16 2006-09-26 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Country Status (12)

Country Link
EP (1) EP1765319A1 (uk)
JP (1) JP2007532605A (uk)
CN (1) CN1942180A (uk)
AU (1) AU2005244483B2 (uk)
BR (1) BRPI0509878A (uk)
CA (1) CA2504280A1 (uk)
IL (1) IL178300A0 (uk)
MX (1) MX291518B (uk)
RU (1) RU2387448C2 (uk)
UA (1) UA94693C2 (uk)
WO (1) WO2005110393A1 (uk)
ZA (1) ZA200607794B (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
ITMI20100961A1 (it) * 2010-05-27 2011-11-28 Erredue Spa Miscele ricche in esteri di acidi grassi omega-3, loro composizioni e loro processo di preparazione

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ES2238568T3 (es) * 2001-05-30 2005-09-01 Laxdale Limited Uso del coenzima q (ubiquinona) y acido eicosapentaenoico (epa) para el tratamiento del linfoma no hodgkin y trastornos psiquiatricos o neurologicos.

Also Published As

Publication number Publication date
RU2006140277A (ru) 2008-05-27
AU2005244483B2 (en) 2011-06-09
MX291518B (es) 2011-10-31
BRPI0509878A (pt) 2007-10-16
UA94693C2 (uk) 2011-06-10
JP2007532605A (ja) 2007-11-15
CA2504280A1 (en) 2005-10-16
CN1942180A (zh) 2007-04-04
EP1765319A1 (en) 2007-03-28
RU2387448C2 (ru) 2010-04-27
WO2005110393A1 (en) 2005-11-24
MXPA06011940A (es) 2006-12-15
ZA200607794B (en) 2008-05-28
AU2005244483A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
MX2009003921A (es) Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b.
PL1641918T3 (pl) Komórki poporodowe do zastosowania w leczeniu choroby serca i układu krążenia
AU2002367535A8 (en) Diagnosis and treatment of vascular disease
NO20033304L (no) Essensielle N-3 fettsyrer i kardialinsuffisiens- og hjertesviktterapi
IL181234A0 (en) Mixture of phytosterol ester(s) and 1,3-diglycerides(s) for use in the treatment of medical conditions
IL160917A0 (en) Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
SI2034999T1 (sl) DHA estri in uporaba le-teh pri zdravljenju in preprečevanju kardiovaskularnih bolezni
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
EP1736149A3 (en) Astaxanthin-containing agent for lowering neutral fat concentration in blood
AU2003233681A8 (en) Diagnosis and treatment of human dormancy syndrome
AU2003298768A8 (en) Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
EP1750734A4 (en) PROCESS FOR THE PREPARATION AND USE OF FIBRINOLYTIC ENZYMES FOR THE TREATMENT OF DISEASES
IL176027A0 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
IL178300A0 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
IL162941A0 (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
IL179560A0 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
EP1664775A4 (en) COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME
WO2001091785A3 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
ZA200610297B (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
AU2002319591A1 (en) Diagnosis and treatment of vascular disease